Fulcrum Therapeutics, Inc.
FULCFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Fulcrum Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Fulcrum Therapeutics, Inc. — 10-K filed Feb 24, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 8 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 30, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| FMR LLC | 2026-03-31 | 61,041 | $468K | SEC filing |
| DIMENSIONAL FUND ADVISORS LP | 2026-03-31 | 1,130,281 | $8.66M | SEC filing |
| China Universal Asset Management Co., Ltd. | 2026-03-31 | 11,819 | $90.7K | SEC filing |
| ProShare Advisors LLC | 2026-03-31 | 11,656 | $89.4K | SEC filing |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 2026-03-31 | 472 | $3.62K | SEC filing |
| BESSEMER GROUP INC | 2026-03-31 | 286,988 | Not shown | SEC filing |
| FEDERATED HERMES, INC. | 2026-03-31 | 328 | $2.52K | SEC filing |
| Sterling Capital Management LLC | 2026-03-31 | 1,849 | $14.2K | SEC filing |
| ADAR1 Capital Management, LLC | 2026-03-31 | 130,560 | $1M | SEC filing |
| PROFUND ADVISORS LLC | 2026-03-31 | 15,501 | $119K | SEC filing |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 2026-03-31 | 28,080 | $215K | SEC filing |
| WELLS FARGO & COMPANY/MN | 2026-03-31 | 22,551 | $173K | SEC filing |
| Farther Finance Advisors, LLC | 2026-03-31 | 2,390 | $17.9K | SEC filing |
| BRAIDWELL LP | 2026-03-31 | 3,134,922 | $24M | SEC filing |
| BARCLAYS PLC | 2026-03-31 | 88,458 | $678K | SEC filing |
| AMERICAN CENTURY COMPANIES INC | 2026-03-31 | 156,242 | $1.2M | SEC filing |
| Ikarian Capital, LLC | 2026-03-31 | 1,049,161 | $8.05M | SEC filing |
| Mirae Asset Global Investments Co., Ltd. | 2026-03-31 | 3,474 | $26.6K | SEC filing |
| Pale Fire Capital SE | 2026-03-31 | 26,100 | $200K | SEC filing |
| Jump Financial, LLC | 2026-03-31 | 369,805 | $2.84M | SEC filing |
- Each value is checked against Fulcrum Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Fulcrum Therapeutics, Inc.'s share price.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Fulcrum Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2023-01-20 · RA Capital Healthcare Fund LP: Larger than all 12 other insider purchases of Common Stock on file. SEC filing
- 2022-12-16 · RA Capital Healthcare Fund LP: Larger than 11 of the 12 other insider purchases of Common Stock on file. SEC filing
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-26 | Ezekowitz Alan · Director | Common Stock | S — Open market or private sale | −18,000 | 3.65 | SEC filing |
| 2026-02-02 | Gould Robert J · Director | Common Stock | S — Open market or private sale | −15,000 | 10.72 | SEC filing |
| 2026-01-02 (amended) | Gould Robert J · Director | Common Stock | S — Open market or private sale | −15,000 | 10.87 | SEC filing |
| 2026-01-02 | Gould Robert J · Director | Common Stock | S — Open market or private sale | −15,000 | 11.87 | SEC filing |
| 2025-12-15 | Oltmans Curtis Gale · Chief Legal Officer | Common Stock | S — Open market or private sale | −3,452 | 12.92 | SEC filing |
| 2025-12-08 | RA Capital Healthcare Fund LP · 10% owner | Common Stock | S — Open market or private sale | −91,722 | 14.98 | SEC filing |
| 2025-12-08 | RA Capital Healthcare Fund LP · 10% owner | Common Stock | S — Open market or private sale | −1,377,020 | 13.33 | SEC filing |
| 2025-12-08 | RA Capital Healthcare Fund LP · 10% owner | Common Stock | S — Open market or private sale | −2,706,397 | 14.28 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-04-23 | Lehrer-Graiwer Joshua · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +64,000 | SEC filing |
| 2026-02-02 | Musso Alan A · Chief Financial Officer | Stock Option (right to buy) | A — Grant, award, or other acquisition | +170,000 | SEC filing |
| 2026-02-02 | Sapir Alex · See Remarks | Stock option - Right to Buy | A — Grant, award, or other acquisition | +650,000 | SEC filing |
| 2026-02-02 | Oltmans Curtis Gale · Chief Legal Officer | Stock Option (right to buy) | A — Grant, award, or other acquisition | +170,000 | SEC filing |
| 2026-02-02 | Tourangeau Greg · Principal Accounting Officer | Stock Option (right to buy) | A — Grant, award, or other acquisition | +57,000 | SEC filing |
| 2025-06-26 | Ezekowitz Alan · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +36,000 | SEC filing |
| 2025-06-26 | GERAGHTY JAMES A · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +36,000 | SEC filing |
| 2025-06-26 | Dorton Katina · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +36,000 | SEC filing |
Showing 8 of 21 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2024-08-21 | RA Capital Healthcare Fund LP · 10% owner | Warrant (Right to Buy) | J — Other acquisition or disposition | +8,500,000 | SEC filing |
| 2024-08-21 | RA Capital Healthcare Fund LP · 10% owner | Common Stock | J — Other acquisition or disposition | −8,500,000 | SEC filing |
| 2022-12-13 | TEPPER ROBERT I · 10% owner | Common Stock | J — Other acquisition or disposition | −2,000,000 | SEC filing |
| 2022-06-28 | Ezekowitz Alan · Director | Stock Option (right to buy) | J — Other acquisition or disposition | −500 | SEC filing |
| 2021-11-10 | LEVIN MARK J · Director, 10% owner | Common Stock | J — Other acquisition or disposition | −1,000,000 | SEC filing |
| 2021-11-10 | TEPPER ROBERT I · 10% owner | Common Stock | J — Other acquisition or disposition | −1,000,000 | SEC filing |
| 2021-09-22 | TEPPER ROBERT I · 10% owner | Common Stock | J — Other acquisition or disposition | −1,000,000 | SEC filing |
| 2021-09-22 | LEVIN MARK J · Director, 10% owner | Common Stock | J — Other acquisition or disposition | −1,000,000 | SEC filing |
Showing 8 of 8 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.